Below are the most recent publications written about "Arabinonucleosides" by people in Profiles.
-
Akahane K, Murakami Y, Kagami K, Abe M, Harama D, Shinohara T, Watanabe A, Goi K, Nishi R, Yamauchi T, Kimura S, Takita J, Look AT, Minegishi M, Sugita K, Inukai T. High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia. Hematol Oncol. 2019 Oct; 37(4):516-519.
-
Messinger Y, Boklan J, Goldberg J, DuBois SG, Oesterheld J, Abla O, Martin A, Weinstein J, Hijiya N. Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia. Pediatr Hematol Oncol. 2017 May; 34(4):187-198.
-
Luskin MR, Ganetsky A, Landsburg DJ, Loren AW, Porter DL, Nasta SD, Svoboda J, Luger SM, Frey NV. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. Br J Haematol. 2016 07; 174(2):332-4.
-
El-Jawahri A, Li S, Ballen KK, Cutler C, Dey BR, Driscoll J, Hunnewell C, Ho VT, McAfee SL, Poliquin C, Saylor M, Soiffer RJ, Spitzer TR, Alyea E, Chen YB. Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):80-5.
-
Roberts DA, Wadleigh M, McDonnell AM, DeAngelo DJ, Stone RM, Steensma DP. Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Leuk Res. 2015 Feb; 39(2):204-10.
-
Petri CR, O'Donnell PH, Cao H, Artz AS, Stock W, Wickrema A, Hard M, van Besien K. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leuk Lymphoma. 2014 Dec; 55(12):2866-73.
-
Jain P, Kantarjian H, Ravandi F, Thomas D, O'Brien S, Kadia T, Burger J, Borthakur G, Daver N, Jabbour E, Konopleva M, Cortes J, Pemmaraju N, Kelly MA, Cardenas-Turanzas M, Garris R, Faderl S. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014 Apr; 28(4):973-5.
-
Forcade E, Leguay T, Vey N, Baruchel A, Delaunay J, Robin M, Socié G, Dombret H, Peffault de Latour R, Raffoux E. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1124-6.
-
Abramson JS, Takvorian RW, Fisher DC, Feng Y, Jacobsen ED, Brown JR, Barnes JA, Neuberg DS, Hochberg EP. Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study. Leuk Lymphoma. 2013 Sep; 54(9):1915-20.
-
Abraham A, Alsultan A, Jeng M, Rodriguez-Galindo C, Campbell PK. Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis. Pediatr Blood Cancer. 2013 Jun; 60(6):E19-22.